Moors & Cabot’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Moors & Cabot’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-56,500	Closed	-$50.1K	–	944
2022 Q4	$50.1K	Sell	56,500 -2,000	-3%	-$2.65K	﹤0.01%	815
2022 Q3	$92K	Sell	58,500 -3,000	-5%	-$6.8K	0.01%	769
2022 Q2	$124K	Sell	61,500 -1,000	-2%	-$1.73K	0.01%	742
2022 Q1	$146K	Buy	62,500 +50,750	+432%	+$158K	0.01%	796
2021 Q4	$55K	Buy	+11,750	New	+$72.9K	﹤0.01%	839
2020 Q4	–	Sell	-17,650	Closed	-$197K	–	788
2020 Q3	$197K	Buy	+17,650	New	+$162K	0.02%	600

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $177M AUM 286.05% 1-Year Est. Return

Oaktree Capital Management Los Angeles, California $5.91B AUM 42.97% 1-Year Est. Return

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

Crescent Grove Advisors Lake Forest, Illinois $1.01B AUM 17.78% 1-Year Est. Return

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return